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Introduction
Prostate cancer (PCa) is one of the most commonly diagnosed 
malignancies worldwide and a leading cause of cancer-related 
deaths among men.1 Although most cases are clinically indolent, 
a variable proportion of patients develop castration-resistant PCa 
(CRPC), an aggressive and lethal form of disease, associated with 
widespread metastatic disease.2 Currently, most therapeutic strat-
egies are largely ineffective and only allow for a small increase 
in survival.3 Therefore, new therapeutic strategies, ideally based 
on the understanding of the biology of this disease, are urgently 
needed.
PCa is a complex and heterogeneous disease that arises 
through the acquisition of several genetic and epigenetic altera-
tions.4,5 Among the latter, dysregulation of microRNA (miRNA) 
expression has been recently emphasized as a critical mechanism 
in PCa development and progression.6 miRNAs are small non-
coding RNAs that posttranscriptionally regulate gene expression 
by inducing cleavage of their target mRNA or by inhibiting their 
translation.7 These molecules are produced through a multi-step 
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process that involves the RNase III enzymes DROSHA and 
DICER, resulting in the production of mature miRNAs of ~22 
nucleotides, which are incorporated into the RNA-induced silenc-
ing complex (RISC) through the action of the DICER-TRBP 
(Trans-activator RNA-binding protein) complex.8 miRNAs play 
a crucial role in the regulation of almost every biological process, 
including differentiation, apoptosis, cell cycle, development and 
metabolism.9,10 Moreover, dysregulation of any of these processes 
due to abnormal expression of miRNAs or alterations in their 
machinery of biogenesis has been implicated in cancer, includ-
ing PCa.11,12 Although miRNAs have been proposed to function 
as either oncogenes or tumor-suppressor genes,13 most human 
tumors are characterized by a general defect in miRNA produc-
tion that results in global downregulation of miRNA expres-
sion.14-16 Thus, compounds with the ability to restore the global 
miRNA expression might be an excellent therapeutic option for 
cancer.
Enoxacin, an antibacterial compound based on a fluoro-
quinolone skeleton, was shown to be effective in the inhibi-
tion of tumor cell growth in vitro and in vivo by enhancing 
after 2 d of drug exposure. The reduction in the percentage of 
viable cells at day 5 ranged between 17 and 59%, with LNCaP 
being the most responsive cell line (Fig. 2B).
To determine whether enoxacin was capable of inducing sig-
nificant cell death, an apoptosis assay was performed. Indeed, a 
significant increase in apoptosis was apparent in all tested cell 
lines at days 2 and 5 (Fig. 3A). After 5 d of exposure to enoxacin, 
LNCaP and DU145 displayed the highest levels of apoptotic cells 
(Fig. 3A).
Apoptosis was also confirmed at molecular level, through the 
evaluation of mRNA expression of CASP3. Although all cell lines 
showed an increase in CASP3 expression levels, statistically signifi-
cant differences were depicted only for LNCaP, 22Rv1 and DU145 
(Fig. 3B). Furthermore, cleaved PARP was analyzed after enoxa-
cin exposure. 22Rv1, VCaP and DU145 presented increased pro-
tein levels of cleaved PARP after exposure to the drug (Fig. 3C).
Cell cycle distribution was evaluated by flow cytometry. 
Interestingly, 22Rv1 and VCaP, which are hormone-responsive 
PCa cell lines, showed cell cycle arrest at G2/M, whereas the 
castration-resistant cell lines DU145 and PC-3 exhibited a sig-
nificant increase in the percentage of cells in late S and G2/M 
transition (Fig. 4; Fig. S2).
Moreover, the percentage of cells in sub-G1 phase, which is 
an indirect measure of cell death, increased significantly after 
enoxacin exposure (Table 1; Fig. S2). Thus, both the increase of 
apoptotic cells and cell cycle arrest support a growth inhibitory 
effect of enoxacin on PCa cells.
The effect of enoxacin on the invasiveness of PCa cells 
was only assessed in LNCaP and DU145 cell lines because, as 
described in the previous experiments, these cells were the most 
responsive to enoxacin. We decided to extend enoxacin exposure 
from 5 to 8 d in order to allow the vehicle cells to invade. In 
contrast to DU145, LNCaP cells did not show invasive potential 
in this system. Remarkably, enoxacin significantly reduced the 
invasiveness of DU145 cells (Fig. 5).
Enoxacin restores miRNAs expression. The impact of enoxa-
cin exposure on the expression profile of miRNAs was analyzed 
in LNCaP and DU145 cell lines, using a panel of 742 miRNAs. 
miRNA analysis demonstrated that enoxacin induced a global 
upregulation of miRNA expression in both cell lines. Among 
miRNAs differentially expressed, upregulation was observed in 
53% of the miRNAs (65 of 122) for LNCaP cells (Fig. 6A; Table 
S1) and in 60% (147 of 247) for DU145 (Fig. 6A; Table S2).
Remarkably, enoxacin was able to alter the expression of sev-
eral miRNAs that have been previously associated with prostate 
carcinogenesis. Concerning tumor-suppressor miRNAs reported 
in PCa, miR-17*, miRNA-29b, miR-34a, miR-132, miR-146a 
and miR-449a showed increased expression levels following 
enoxacin exposure. Furthermore, decreased expression of some 
oncogenic miRNAs was also observed, including miR-141 and 
miR-191 (Table 2).
To confirm the impact of enoxacin on miRNA targets, protein 
expression levels of HDAC1, a miR-449a target oncoprotein, and 
SIRT1, a miR-34a target oncoprotein, were assessed by Western 
Blot. Both cell lines after drug exposure displayed decreased pro-
tein levels of HDAC1 and SIRT1 (Fig. 6B).
the production of miRNAs with tumor suppressor functions.17 
Remarkably, the drug did not affect normal cells and was not 
associated with toxicity in mice models.17 Moreover, it has been 
reported that enoxacin promotes RNA interference (RNAi) and 
miRNA biogenesis by facilitating the interaction between TRBP, 
encoded by the Trans-activator RNA-binding protein 2 (TARBP2) 
gene, and miRNA precursors.17,18 Therefore, it has been recently 
demonstrated that TARBP2-mutant cells are less responsive to 
enoxacin.17,19 Although those results are promising for cancer 
therapeutics, no studies are available concerning the effect of 
enoxacin on PCa. Thus, we aimed to investigate the effectiveness 
of enoxacin as a tumor growth inhibitor in PCa. Furthermore, we 
evaluated the alterations in miRNA expression induced by this 
compound in PCa cells.
Results
PCa cells do not harbor TARBP2 mutations and retain TRBP 
protein expression. In view of the fact that cell lines harbor-
ing TARBP2 mutations are less responsive to enoxacin,17,19 five 
PCa cell lines (LNCaP, 22Rv1, VCaP, DU145 and PC-3) were 
screened for the presence of mutations in all the exonic mono-
nucleotide repeats localized in the coding sequences of TARBP2. 
Co115, a TARBP2-mutant colorectal cancer cell line,17,19 was used 
as positive control. No TARBP2 mutations were found in any 
of the tested PCa cell lines. Subsequently, we analyzed TRBP 
protein expression in PCa cell lines by western blot. As expected, 
all PCa cell lines expressed higher protein levels of TRBP than 
Co115 cells, which display very low expression levels (Fig. 1A). 
Since DICER acts in complex with TRBP,8 we also assessed 
DICER protein expression in PCa cell lines, and we verified that 
all PCa cell lines tested expressed DICER (Fig. 1A).
Primary PCa tumors are TARBP2 wild type and express 
TRBP. To investigate the putative clinical usefulness of enoxacin 
for PCa therapy, we first assessed the TARBP2 mutational status 
of 25 primary PCa tumors, and only wild type sequences were 
detected. Furthermore, using immunohistochemistry, TRBP 
expression was evaluated in a series of 50 primary PCa tumors, 
including the same cases analyzed for TARBP2 mutational sta-
tus. No differences in immunoreactivity for TRBP were apparent 
between normal and tumorous prostatic tissues representing dif-
ferent histopathological grades (Fig. 1B).
Enoxacin reverts neoplastic features of PCa cell lines. The 
half-maximal effective concentration (EC
50
) of enoxacin was cal-
culated in LNCaP and DU145 prostate cancer cells lines at 72 
h. The drug presented an EC
50
 of 105 μM in LNCaP and 141
μM in DU145. Thus, to evaluate the effects of enoxacin, five
human PCa cell lines were continuously exposed for 5 d to 124
μM (40 μg/mL) of enoxacin. As expected, enoxacin did not alter
the expression of both TRBP and DICER proteins in any of the
analyzed cell lines (Fig. 2A).
Importantly, a significant decrease in the number of viable cells 
was observed after exposure to the drug when compared with the 
vehicle, DMSO (Fig. 2B). For LNCaP and 22Rv1 cell lines, the 
effect was observed from day 1, whereas a significant decrease in 
the number of viable cells in VCaP, DU145 and PC-3 was found 
which results in progressive clinical deterioration and, ultimately, 
death.21,22 For patients with CRPC, there are limited treatment 
options with proven survival benefit.23-26
Recently, several miRNA microarray profiles demonstrated 
that miRNAs are commonly dysregulated in PCa when com-
pared with normal prostate tissue and that they are also differ-
entially expressed in different stages of PCa.15,16 Hence, miRNAs 
Discussion
PCa is one of the leading causes of cancer-related deaths world-
wide,1 and almost all of those deaths occur as a result of the emer-
gence of castration-resistant disease.20 Although PCa patients 
initially respond to androgen-deprivation therapy, about 18–24 
months after treatment initiation, most patients develop CRPC, 
Figure 1. TRBp and DIcER expression in pca. (A) TRBp and DIcER expression was assessed by Western Blot in pca cell lines. The picture is representa-
tive of three independent experiments. β-actin was used as a loading control and the relative density of bands was densitometrically quantified. Mean 
quantitation values are shown. co115, a TARBP2-mutant colon carcinoma-derived cell line, was used as positive control. (B) Immunohistochemical stain 
for TRBp expression in prostatic tissue. protein immunoexpression in tumor cells was similar to that of normal epithelial cells. Normal glands (B1), and 
tumorous tissue: Gleason score 6 (B2), Gleason score 7 (B3), and Gleason score 8 (B4).
Until now, few studies have reported the use of these synthetic 
miRNAs as tumor suppressors and, additionally, the effective 
technology for delivery of these oligonucleotide-based therapies 
remains a problem.28 Because most human cancers exhibit global 
miRNA downregulation,14-16 the search for compounds able to 
globally restore the expression of tumor-suppressor miRNAs 
might be used not only as diagnostic and prognostic biomarkers 
but also as therapeutic targets in PCa. In recent years, efforts 
have been made to find effective miRNA-based therapeutic 
strategies for cancer. Indeed, artificial miRNAs that might act 
as potential anti-tumoral agents are the most studied so far, with 
most reports focusing on oncogenic miRNAs inhibition.27,28 
Figure 2. (A) Effect of enoxacin on the expression of TRBp and DIcER. protein expression of TRBp and DIcER was analyzed by Western Blot in LNcap, 
22Rv1, Vcap, DU145 and pc-3 cell lines after exposure to enoxacin 40 μg/mL or DMsO (vehicle) at day five. The picture is representative of three inde-
pendent experiments. β-actin was used as a loading control and the relative density of bands was densitometrically quantified. (B) Effect of enoxacin 
on pca cell viability. cell viability was evaluated by MTT assay in LNcap, 22Rv1, Vcap, DU145 and pc-3 cell lines after exposure to enoxacin 40 μg/mL or 
DMsO (vehicle) for 5 d. The number of cells/mL is shown as mean of three independent experiments performed in triplicates ± sD. statistical signifi-
cance (enoxacin vs. vehicle) was tested using the two-sided student’s t-test *p < 0.05, **p < 0.01, ***p < 0.001, compared with vehicle group.
Figure 3. Effect of enoxacin on pca cell apoptosis. (A) apoptosis was analyzed by apOpercentage assay at days two and five in LNcap, 22Rv1, Vcap, 
DU145 and pc-3 cell lines after exposure to enoxacin 40 μg/mL or DMsO (vehicle) at days two and five. (B) CASP3 mRNa expression was evaluated by 
qRT-pcR in LNcap, 22Rv1, Vcap, DU145 and pc-3 cell lines after exposure to enoxacin 40 μg/mL or DMsO (vehicle) at day five. Data are presented as 
mean of three independent experiments performed in duplicates ± sD. statistical significance (enoxacin vs. vehicle) was tested using the two-sided 
student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001, compared with vehicle group. (C) cleaved paRp was analyzed by Western Blot in LNcap, 22Rv1, 
Vcap, DU145 and pc-3 cell lines after exposure to enoxacin 40 μg/mL or DMsO (vehicle) at day five. The picture is representative of three independent 
experiments. β-actin was used as a loading control and the relative density of bands was densitometrically quantified.
mutations.17,19 Thus, we initially screened PCa cell lines for 
TARBP2 mutations and none was found, although we were able 
to confirm a TARBP2 mutation in the control, colorectal cancer 
cell line Co115, as previously reported.17,19 To further validate 
our results, we performed western blot for TRBP and confirmed 
that all PCa cell lines tested displayed higher protein levels than 
Co115, in agreement with previous studies.17,19 The TARBP2 
mutational status was also assessed in primary PCa tumors and 
only wild type sequences were detected. We then interrogated 
primary PCa cases using an immunohistochemistry assay for 
TRBP and we found that protein immunoexpression in tumor 
cells was similar to that of normal epithelial cells. Thus, we may 
infer that primary prostate carcinomas do not harbor deleteri-
ous mutations at the TARBP2 locus and display normal levels of 
TRBP protein, rendering them sensitive to restoration of normal 
miRNA biogenesis by enoxacin.
To demonstrate the growth-inhibitory effect of enoxacin on 
PCa cell lines, we assessed cell viability, apoptosis and cell cycle 
characteristics following five-day exposure. Remarkably, in all 
tested cell lines, exposure to enoxacin resulted in a significant 
decrease in cell viability and induction of cell death by apop-
tosis, as previously demonstrated for other cancer cell lines.17 
These results were further confirmed at the molecular level 
remains a priority in miRNA research. Herein, we report for the 
first time the anti-cancer effect of enoxacin, one of such com-
pounds, on PCa cell lines.
Enoxacin, which has been used as a broad-spectrum antibiotic 
to treat bacterial infections (e.g., urinary tract infections),29,30 
was recently reported as being capable of enhancing RNAi 
and consequently induce miRNA expression.17,18 However, the 
mechanism of action of enoxacin is dependent of TRBP as it 
has been shown that this compound is less effective in cells 
harboring alterations in this protein caused by TARBP2 gene 
Figure 4. Effect of enoxacin on pca cell cycle distribution. cell cycle distribution was assessed by flow cytometry in LNcap, 22Rv1, Vcap, DU145 and 
pc-3 cell lines after exposure to enoxacin 40 μg/mL or DMsO (vehicle) at day five. The percentage of cells is shown as mean of three independent 
experiments ± sD. statistical significance (enoxacin vs. vehicle) was tested using the two-sided student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001, 
compared with vehicle group.
Table 1. Impact of enoxacin on the percentage of cells in sub-G1 phase 
assessed by flow cytometry
Cell Line
Cells in Sub-G1 phase (%)
p value
Vehicle Enoxacin
LNcap 1.7 2.0 ns
22Rv1 1.8 13.1 < 0.001
Vcap 2.5 7.3 0.002
DU145 1.7 7.5 < 0.001
pc-3 1.0 3.6 0.004
Ns, non-significant.
of PCa cells through inhibition of mitochondrial antioxidant 
enzymes.35 On the other hand, miR-34a, which presents tumor-
suppressor functions, inhibits silent information regulator 1 
(SIRT1), a gene that suppresses p53-dependent apoptosis.36,37 
Finally, miR-449a, which is underexpressed in PCa, regulates 
cell growth and viability by repressing HDAC1.33 Remarkably, 
in LNCaP and DU145 cell lines, upregulation of miR-449 by 
enoxacin resulted in the downregulation of HDAC1, an onco-
protein expressed at significantly higher levels in PCa than 
in normal prostate.38,39 Moreover, in LNCaP cells, upregula-
tion of miR-34a by enoxacin induced the downregulation of 
SIRT1, which is overexpressed in PCa.40 On the contrary, in 
DU145, SIRT1 downregulation cannot be attributed to miR-
34a, as this was not found to be upregulated following enoxacin 
exposure. However, because SIRT1 may be regulated by other 
miRNAs, this hypothesis may not be ruled out completely at 
this point. In spite of globally upregulating the expression of 
miRNAs, enoxacin also caused a decrease in the expression of 
some oncogenic miRNAs, including miR-14141 and miR-191,42 
reported as oncomiRs in PCa. miR-141 is a target of andro-
gen regulation and it has been suggested that its upregulation 
may enhance the growth of CRPC cells.41 Finally, although less 
studied, miR-191 has also been reported as being overexpressed 
in PCa.42 Thus, the simultaneous upregulation of tumor-sup-
pressor miRNAs and downregulation of oncomiRs by enoxacin 
in PCa cells highlights the therapeutic relevance of this drug in 
PCa. Notwithstanding, enoxacin also affected the expression 
levels of several other miRNAs, which play a role in different 
types of cancer, but with an unknown function in PCa. Thus, 
further studies are mandatory to disclose the biological func-
tion of these miRNAs in PCa.
In conclusion, enoxacin constitutes a promising therapeutic 
agent and in vivo studies should be conducted to further sup-
port the potential of enoxacin for therapy of PCa patients.
through the observed statistically significant increase in CASP3 
mRNA expression for three of the five cell lines analyzed 
(LNCaP, 22Rv1 and DU145). Regarding protein expression of 
cleaved PARP, we also observed an increase after exposure to the 
drug in three cell lines (22Rv1, VCaP and DU145). Although 
the percentage of cells in Sub-G1 differs among the tested cell 
lines, globally there is an increase after exposure to enoxacin. 
With some variations, CASP3 mRNA, and cleaved PARP pro-
tein expression follow the same trend. The percentage of cells 
in Sub-G1 may also reflect cell death due to necrosis or other 
mechanisms, but the results of the remaining three parameters 
(CASP3 mRNA levels, APOPercentage and cleaved PARP) 
strongly indicate that apoptosis is, indeed, the main mecha-
nism underlying cell death in this study. Concerning cell cycle 
distribution, it was observed that 22Rv1 and VCaP, which are 
hormone-responsive PCa cell lines, presented cell cycle arrest at 
G2/M, whereas the castration-resistant cell lines DU145 and 
PC-3 exhibited an increase in the percentage of cells at late S 
and G2/M transition.
Furthermore, we have shown for the first time that enoxa-
cin significantly reduce the invasive potential of PCa cells. As 
metastasis is the major cause of morbidity and mortality in 
PCa patients,4 the development of new treatment regimens that 
would reduce tumor dissemination is extremely important for 
PCa therapy. It could be argued that the impact of enoxacin 
on cell invasion might be the result of reduced cell viability. 
However, it should be pointed out that it is difficult to dissociate 
one feature from the other, as both are likely to act in concert. 
Indeed, if tumor cell viability is reduced, it is expected that the 
potential to invade is also impaired. Irrespective of the underly-
ing cause, however, our results demonstrate that a reduction in 
invasive potential does occur after exposure to enoxacin.
The ability to disrupt pathways of cancer cell survival has 
been already reported for a broad spectrum of cancer cells, both 
in vitro and in vivo, through the enhancement of the miRNA-
processing machinery.17
In this study, we also demonstrated that enoxacin was 
effective in globally restoring the expression of miRNAs. 
Nevertheless, we found a decrease in the expression of a signifi-
cant number of miRNAs, which is not totally in agreement with 
the mechanism of action purposed for enoxacin.17,19 According 
to previous studies, the presence of enoxacin increases the bind-
ing affinity of TRBP for miRNA precursors promoting miRNA 
biogenesis.17,19 Hence, it is tempting to speculate that besides 
this mechanism there might be other pathways through which 
enoxacin exerts its action.
Importantly, upregulation of several tumor-suppressor miR-
NAs known to be involved in PCa development and progression 
was observed, including miR-29b,31,32 miR-449a,33 miR-146a,34 
miR-17*35 and miR-34a.36,37 For instance, miRNA-29b was 
reported to be a negative regulator of PCa cell growth by modu-
lating the expression of multiple proteins implicated in metasta-
sis formation, including MMP2, E-cadherin, N-cadherin, Snail 
and Twist.31,32 miR-146a is downregulated in CRPC cell lines, 
and targets ROCK1 and EGFR, which are implicated in the 
development of CRPC.34 miR-17* also suppresses tumorigenicity 
Figure 5. Effect of enoxacin on the invasive potential of pca cells. 
Relative invasion was evaluated by Oris™ cell Invasion assay in DU145 
cell line after exposure to enoxacin 40 μg/mL or DMsO (vehicle) at 
day eight. Data are presented as mean of three independent experi-
ments performed in triplicates ± sD. statistical significance (enoxacin 
vs. vehicle) was tested using the two-sided student’s t-test. **p < 0.01, 
compared with vehicle group.
Health Sciences Research Institute at the University of Minho 
(Braga, Portugal). All cell lines were cultured in the recom-
mended medium, supplemented with 10% fetal bovine serum 
and 1% Penicillin-Streptomycin (GIBCO). Cells were main-
tained at 37°C in a humidified atmosphere containing 5% CO
2
. 
All PCa cell lines were karyotyped by G-banding (for validation 
purposes) and routinely tested for Mycoplasma spp contamina-
tion (PCR Mycoplasma Detection Set, Clontech Laboratories). 
Enoxacin (Sigma-Aldrich) was dissolved in dimethyl sulfoxide 
(DMSO) (Sigma-Aldrich) and stored at −20°C until further use. 
PCa cells were continuously exposed to 40 μg/mL (124 μM) 
enoxacin, for 5 d. For control purposes, cell lines were exposed to 
the vehicle of the drug (DMSO) only.
Direct sequencing. Genomic DNA was extracted from cell 
lines and prostatic cancer tissue using a standard technique 
comprising digestion with proteinase K (20 mg/mL) in the 
presence of 10% SDS at 55°C, followed by phenol-chloroform 
extraction and precipitation with 100% ethanol.43 TARBP2 was 
screened for mutations using the primers previously described 
by Melo et al.19 Direct sequencing was performed in an ABI 
PRISM 310 automatic sequencer using Big Dye Terminator 
Chemistry (Applied Biosystems), according to the manufac-
turer’s recommendations.
Western blot. Protein extraction from whole-cell lysates was 
obtained using RIPA lysis buffer (Santa Cruz Biotechnology). 
Protein concentrations were determined using a Pierce BCA 
assay (Thermo Scientific Inc.), according to the manufac-
turer’s instructions. Briefly, 30 μg of protein from each sample 
were separated using 10% Mini-PROTEAN® TGX™ Precast 
Gel (Bio-Rad) at 200 V and subsequently blotted onto Protran 
nitrocelulose transfer membranes (Whatman) using Trans-Blot® 
Turbo™ Transfer System (Bio-Rad). Membranes were incubated 
with primary antibodies at 4°C overnight. Primary antibodies 
were polyclonal rabbit against TRBP (1:1,000, Abcam), poly-
clonal rabbit against DICER (1:500, Santa Cruz Biotechnology), 
monoclonal mouse against cleaved PARP (1:500, Cell Signaling), 
monoclonal mouse antibody against HDAC1 (1:1,000, Sigma-
Aldrich) and polyclonal rabbit against SIRT1 (1:1000, Abcam). 
The membranes were developed using Immun-Star WesternC 
Chemiluminescent kit (Bio-Rad) and exposed to Amersham 
Hyperfilm (GE Healthcare). To ascertain equal loading of pro-
tein, the membranes were stripped and reprobed with a monoclo-
nal mouse antibody against β-Actin (1:8,000, Sigma-Aldrich). 
To relate the protein band intensity with the loading control 
(β-Actin), protein band intensities were determined using 
Quantity One software (Bio-Rad).
Patients and sample collection. Fifty prostate tumor samples 
from patients with clinically localized PCa (clinical stage II: 
T1cN0M0 or T2N0M0, according to the TNM staging system) 
consecutively diagnosed and primarily treated with radical pros-
tatectomy at the Portuguese Oncology Institute Porto, Portugal, 
were prospectively collected from 2001 to 2006. Tumor tissue 
was routinely fixed in buffered formalin and paraffin-embed-
ded. All patients were enrolled after informed consent. This 
study was approved by the institutional review board (Comissão 
de Ética do IPO Porto).
Materials and Methods
Cell lines, drug preparation and exposure. DU145 was obtained 
from the American Type Culture Collection (ATCC), whereas 
LNCaP, VCaP and PC-3 were kindly provided by Prof. Ragnhild 
A. Lothe from the Department of Cancer Prevention at The
Institute for Cancer Research (Oslo, Norway) and 22Rv1 by Dr.
David Sidransky from the Johns Hopkins University School of
Medicine (Baltimore, MD). For control purposes, we used the
human colon carcinoma-derived cell line Co115, which was
kindly provided by Prof. Fátima Baltazar from the Life and
Figure 6. Enoxacin impact on miRNa. (A) Venn diagrams depicting the 
number of differentially expressed miRNas after enoxacin exposure 
compared with the vehicle group. Top, miRNas with increased expres-
sion (fold change ≥ 1.5); bottom, miRNas with decreased expression 
(fold change ≤ −1.5). (B) protein expression of two miRNa targets 
(hDac1 and sIRT1) was analyzed by Western Blot in LNcap and DU145 
cell lines after exposure to enoxacin 40 μg/mL or DMsO (vehicle) at day 
five. The picture is representative of three independent experiments. 
β-actin was used as a loading control and the relative density of bands 
was densitometrically quantified.
in the dark. Cell cycle data were collected using Cytomics FC500 
flow cytometer (Beckman Coulter) and analyzed with Modfit LT 
(Verity Software House Inc.).
Cell invasion assay. Cell invasion was evaluated using the 
Oris™ Cell Invasion Assay (Platypus Technologies) according 
to the manufacturer’s instructions. After starvation for 18 h in a 
serum-free medium, cells were seeded at 5 × 104 cells per well and 
exposed to 40 μg/mL of enoxacin or DMSO for 8 d. At this time 
point, cells were labeled with Calcein AM (AnaSpec) at a final 
concentration of 0.5 μg/mL. A detection mask was attached to 
the bottom of the plate to block from view all cells except those 
that had invaded into the center zone and fluorescence was mea-
sured at excitation and emission wavelengths of 492 nm and 530 
nm, respectively, using a microplate reader (Fluostar Omega). The 
results were expressed as the ratio of the fluorescence index (FI) 
of the cells exposed to enoxacin to that of vehicle cells (set as 1).
Quantitative reverse transcription PCR (qRT-PCR). RNA 
was extracted from all cell lines using TRIzol® (Invitrogen) 
according to manufacturer’s instructions and cDNA was syn-
thesized using the High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems). CASP3 mRNA expression levels were 
assessed using TaqMan gene expression assay, purchased as pre-
developed assays from Applied Biosystems. The mean quantity 
of CASP3 expression levels of cell lines samples was normalized 
against mean quantity of the respective endogenous control 
(GUSB) expression levels.
miRNA expression assessment by miRCURY LNA™ array. 
cDNA synthesis and real-time qRT-PCR was performed using 
the miRCURY LNA™ Universal RT microRNA PCR system 
(Exiqon) according to the manufacturer’s instructions. In brief, the 
cDNA products were transferred to the Ready-to-use microRNA 
PCR Human Panels (I + II) and quantified using SYBR green 
based real-time PCR and LNA enhanced miRNA specific prim-
ers. Based on miRBase 11.0 annotation, a total of 757 human 
miRNA probes were interrogated in this platform. Three indepen-
dent experiments were performed. The data were imported into 
GenEX software (MultiD Analyses AB) for subsequent microar-
ray analysis. Global mean normalization was used as a normaliza-
tion factor for miRNA.44 miRNAs with fold change above 1.5 or 
below −1.5 were considered up or downregulated, respectively.
Immunohistochemistry. TRBP expression in tumor tis-
sue samples was assessed by immunohistochemistry using 
the Novolink™ Polymer Detection System (Novocastra). 
Deparaffinized tissue sections were submitted to antigen retrieval 
in a 700-W microwave oven, in 1x EDTA buffer solution. 
Endogenous peroxidase activity was blocked by incubating the 
slides with Peroxidase Block (Novocastra) for 5 min. The slides 
were incubated with Protein Block (Novocastra) for 5 min, and 
after incubation, primary antibody against TRBP (1:100, Abcam) 
was applied for 1 h in a humid chamber, at room temperature. The 
slides were then incubated with Post Primary Block (Novocastra) 
for 30 min followed by incubation for 30 min with the NovoLink 
Polymer (Novocastra). After incubation in 3,3-diaminobenzidine 
(DAB; Sigma-Aldrich) in a solution of 50 mL PBS/0.05% mL 
H
2
O
2
 for 7 min, the slides were counterstained with hematoxy-
lin (Harris Modified Hematoxylin Stain; Fisher Scientific) for 20 
sec and mounted with Entellann (Merck KGaA). Colorectal can-
cer tissues showing intense immunoreactivity for TRBP protein 
were used as positive control. The negative control consisted on 
the omission of the primary antibody. The assessment of immu-
nostaining results was performed by an experienced pathologist 
and was expressed in a semiquantitative way according to the 
estimated percentage of positive tumor cells. Immunostaining of 
more than 10% of the tumor cells was required for scoring a case 
as positive.
Cell viability assay. Cell viability was evaluated using the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide 
(MTT) assay. In brief, PCa cells were seeded onto 96-well plates 
(Sarstedt) at 2 × 103 cells per well and allowed to adhere overnight. 
After exposure to the drug, cell viability was measured at 1, 2, 3, 
4 and 5 d. Briefly, 200 μL of 0.5 mg/mL MTT (Sigma-Aldrich) 
were added to each well and incubated at 37°C and 5% CO
2
 for 
3 h. Formazan crystals were solubilized with 100 μL of DMSO. 
The absorbance was measured using a microplate reader (Fluostar 
Omega) at a wavelength of 540 nm with background subtraction 
at 630 nm. The number of cells was calculated using the formula: 
[(OD experiment × Number of cells at day 0)/Mean OD at day 0].
Apoptosis assay. Apoptosis evaluation was performed using 
the APOPercentage apoptosis assay kit (Biocolor Ltd.) according 
to the manufacturer’s instructions. This assay is based on phos-
phatidylserine transmembrane movements, which results in the 
uptake of the APOPercentage dye by apoptosis-committed cells. 
Cells were seeded onto 24-well plates (Sarstedt) at 5 × 104 cells 
per well and apoptosis levels were assessed at days 2 and 5. The 
absorbance was determined using a microplate reader (Fluostar 
Omega) at a wavelength of 550 nm with background subtraction 
at 620 nm. To normalize the OD measured in the apoptosis test, 
according to the cell number, the OD of the apoptosis assay was 
divided by the OD of the cell viability assay. The results were 
expressed as the ratio of the OD of the cells exposed to enoxacin 
to that of vehicle cells (set as 1).
Cell cycle analysis. Cell cycle distribution was determined by 
flow cytometry. Briefly, 5 × 105 harvested cells were fixed with 
70% cold ethanol overnight at 4°C. After washing with cold PBS, 
cells were resuspended in staining Propidium Iodide Solution 
(Cytognos S.L.) and incubated at room temperature for 30 min 
Table 2. Effect of enoxacin on the expression of several miRNas already 
implicated in pca
Cell Line miRNAs Fold change p value
LNcap
miR-29b 2.9 0.023
miR-449a 1.8 0.012
miR-34a 2.3 0.014
miR-191 −2.3 0.023
DU145
miR-449a 2.2 0.011
miR-146a 1.8 0.008
miR-29b 1.7 0.004
miR-132 1.7 0.003
miR-17* 1.6 0.008
miR-141 −1.7 0.002
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Statistical analysis. Two-tailed Student’s t-test was used to 
assess differences between the results obtained after exposure to 
enoxacin and after exposure to vehicle. Prior to application of the 
test, all data were transformed to logarithmic scale. Analysis was 
performed with the aid of SPSS software for Windows, version 
20.0 (IBM-SPSS Inc.), and the statistical significance level was 
set at p < 0.05. Graphics were built using MATLAB 7.10.0 r2010a 
software.
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